The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO Asia 2025 | HIMALAYA: STRIDE efficacy and safety in Asian subgroups with uHCC
Changhoon Yoo, MD, PhD, Asan Medical Center, Seoul, South Korea, comments on pooled efficacy and safety outcomes with STRIDE (single tremelimumab regular interval durvalumab) versus sorafenib in patients with unresectable hepatocellular carcinoma (HCC) from mainland China, Hong Kong, and Taiwan enrolled in the Phase III HIMALAYA study (NCT03298451). The analysis highlights consistent survival improvement and a manageable safety profile, supporting the favorable risk-benefit of STRIDE in hepatitis B-prevalent Asian populations. This interview took place at 2025 European Society for Medical Oncology (ESMO) Asia Congress in Singapore, Singapore.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
So, HIMALAYA trial is the pivotal trial of this treatment regimen. It was globally conducted, but at the time, only a small number of patients from the Chinese population were included. So, there was some Chinese extension cohort in the Himalaya trial. So the follow-up duration of the Chinese population was a bit shorter than the original HIMALAYA trial population. So in this sub-Asian subgroup analysis, the Hong Kong and Taiwanese, who also have Chinese ethnicity, were included with the additional Chinese extension cohort...
So, HIMALAYA trial is the pivotal trial of this treatment regimen. It was globally conducted, but at the time, only a small number of patients from the Chinese population were included. So, there was some Chinese extension cohort in the Himalaya trial. So the follow-up duration of the Chinese population was a bit shorter than the original HIMALAYA trial population. So in this sub-Asian subgroup analysis, the Hong Kong and Taiwanese, who also have Chinese ethnicity, were included with the additional Chinese extension cohort. In this cohort, the long-term survival, three-year follow-up data and five-year follow-up data were consistent with the original MLR, the global patient population data, which has proven that the treatment had long-term efficacy. The long-term survival benefit was maintained over the years, and the safety profile was maintained over five years. And yeah, and there is no new safety profile in this Asian sub, Chinese descent subgroup analysis compared with the global patient population.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
